INVESTIGADORES
MORON Victor Gabriel
congresos y reuniones científicas
Título:
NANOSTRUCTURE FROM ASCORBYL PALMITATE BASED-ADJUVANT BOOSTS ADAPTIVE IMMUNITY BY INDUCING AN INFLAMMATORY EFFECT AT THE INJECTION SITE, BOTH PROPERTIES REQUIRE THE ADAPTOR PROTEIN MYD88
Autor/es:
FERNANDA SÁNCHEZ-VALLECILLO; GABRIELA ULLIO; MARÍA MINGUITO DE LA ESCALERA; SANTIAGO PALMA; LETICIA GONZALEZ-CINTADO; ANA CHIODETTI; MARÍA VIRGINIA AGUIRRE; CAROLINA LUQUE BUTELER; G MORON; DANIEL ALLEMANDI; CARLOS ARDAVÍN; MARÍA C. PISTORESI-PALENCIA; BELKYS A. MALETTO
Lugar:
Mar del Plata
Reunión:
Congreso; LXII Reunión de la Sociedad Argentina de Inmunología. Mar del Plata; 2014
Institución organizadora:
Sociedad Argentina de Inmunología
Resumen:
The approved adjuvants for human use induce weak cellular immune responses in subunit vaccines. Thus, the development of new adjuvant strategies is critical. Recently, we have showed that a nanostructure from 6-O-ascorbyl palmitate (Coa-ASC16), used as a platform to formulate CpG-ODN, improved notably its adjuvanticity; one of the possible mechanisms involved is the controlled release given by Coa-ASC16 formulation. In addition, Coa-ASC16 elicits local inflammatory response but how it is sensed is little understood. Here, we begin to understand the underlying mechanisms on the interaction between Coa-ASC16 and immune system after i.p injection. We previously found that the inflammatory response elicited by Coa-ASC16 (neutrophils and monocytes recruitment and IL-1b, IL-6, IL-12) was dependent on MyD88 adaptor protein. TLR2, TLR4 and TLR7 were dispensable matory effect. The administration of Coa-ASC16 was associated with the local release of double-stranded DNA (Coa- ASC16 vs control 2.5±0.5 vs 0.5±0.1 (μg/mL) (p<0.05)). In mice injected locally with DNase or in Tlr9-/- mice, the IL-6 production was inhibited compared to control (pg/mL: 442±167 vs 2231±378 (p<0,001) and 272.4±0.6 vs 1415±322 (p<0.01), respectively). Coa-ASC16 inflammatory activity is independent of NLRP3 signaling. In addition, Coa-ASC16 has itself adjuvant activity when is administrated with OVA antigen, which in turn requires MyD88 and IL-6 cytokine (Myd88-/- vs wt mice: IgG2c: 0.2±0.2 vs 1.6±0.2 (p<0,001), IFN-γ (pg/ml): not detected vs. 931±223; Il6-/- vs wt mice: IgG2c: 0.1±0.1 vs 2.8±0.5 (p<0.01), IFN-γ (pg/ml): 37±37 vs 254±104 (p<0.05)). Mice immunized with OVA were not reactive. Our results show a connection, given by IL-6 cytokine, between the innate and the adaptive response. Coa-ASC16 has not only a platform capacity but also an adjuvant function. Understanding the mechanisms of action of this biomaterial is important for development of safe and effective vaccines.